Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
The purpose of this Notice of Funding Opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults.
Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.
Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.
Agency: Department of Health and Human Services
Office: Food and Drug Administration
Estimated Funding: $900,000
Office: Food and Drug Administration
Estimated Funding: $900,000
Who's Eligible
Obtain Full Opportunity Text:
RFA-FD-25-001 Funding Opportunity Announcement
Additional Information of Eligibility:
See Eligibility Information on page 12 of the attached solicitation document.
Full Opportunity Web Address:
https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-001.html
Contact:
Agency Email Description:
terrin.brown@fda.hhs.gov
Agency Email:
Date Posted:
2024-08-23
Application Due Date:
Archive Date:
2025-11-20
Social Entrepreneurship
Spotlight
Social Enterprises: Key to Enhancing a Nation’s Health
Glasgow Caledonian University (GCU) has launched a series of noteworthy research projects to learn if social enterprises can help Scotland lose its “sick man of Europe” label and boost the nation’s overall health.
Learn How to Identify and Avoid Grant Scams
